zoledronic acid teva
teva b.v. - zoledronska kislina - fractures, bone; cancer - zdravila za zdravljenje bolezni kosti - preprečevanje z okostjem povezanih dogodkov in zdravljenje tumorsko povzročene hiperkalciemije.
conbriza
pfizer europe ma eeig - bazedoksifen - osteoporoza, postmenopavz - spolni hormoni in zdravila genitalni sistem, - zdravilo conbriza je indicirano za zdravljenje postmenopavzalne osteoporoze pri ženskah pri povečanem tveganju zloma. dokazano je bilo znatno zmanjšanje incidence zlomov vretenc; učinkovitost zloma kolka ni bila ugotovljena. pri določanju izbiro conbriza ali drugih terapij, vključno z oestrogens, za posameznika postmenopausal ženska, bi bilo treba preučiti, simptomov menopavze, vplivi na maternice in dojk tkiv, in žilnega tveganja in koristi.
firmagon
ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
kisplyx
eisai gmbh - lenvatinib mesilat - karcinom, ledvična celica - antineoplastična sredstva - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
trialdecal 70 mg tablete + 500 mg/800 i.e. filmsko obložene tablete
meda ab - alendronska kislina - tableta - alendronska kislina 70 mg / 1 tableta - alendronska kislina, kalcij in holekalciferol, zaporedni
trialdecal 70 mg tablete + 500 mg/800 i.e. filmsko obložene tablete
meda ab - alendronska kislina - tableta - alendronska kislina 70 mg / 1 tableta - alendronska kislina, kalcij in holekalciferol, zaporedni
trialdecal 70 mg tablete + 500 mg/800 i.e. filmsko obložene tablete
meda ab - alendronska kislina - tableta - alendronska kislina 70 mg / 1 tableta - alendronska kislina, kalcij in holekalciferol, zaporedni
copalia
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije. copalia je indicirana pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine ali valsartan monotherapy.
exforge
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije. exforge je indicirana pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine ali valsartan monotherapy.